Reprint

Genetic, Epigenetic, Environmental, and Pharmacological Models for Neuroscience, Neurologic Diseases, and Psychiatric Disorders: Advancement in Bench-to-Bedside Translational Research

Edited by
April 2024
248 pages
  • ISBN978-3-7258-0821-2 (Hardback)
  • ISBN978-3-7258-0822-9 (PDF)

This book is a reprint of the Special Issue Genetic, Epigenetic, Environmental, and Pharmacological Models for Neuroscience, Neurologic Diseases, and Psychiatric Disorders: Advancement in Bench-to-Bedside Translational Research that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The Special Issue, "Genetic, Epigenetic, Environmental, and Pharmacological Models for Neuroscience, Neurologic Diseases, and Psychiatric Disorders: Advancement in Bench-to-Bedside Translational Research," delves into the complexities of neurological and psychiatric disorders, which affect millions worldwide. Despite advances, the etiology and pathogenesis of these disorders remain largely unknown, and current treatments often fall short or have adverse effects. This issue emphasizes the urgent need for new strategies to prevent, diagnose, and treat these disorders. It underscores the importance of establishing reliable models that can recapitulate the complex interactions between genetic, epigenetic, environmental, and pharmacological factors contributing to these disorders. The issue presents 12 articles covering a wide range of topics and methods in neuroscience and neurology, highlighting the potential of novel interventions that can modulate the molecular and functional alterations underlying these disorders. It aims to stimulate further research and collaboration among researchers and clinicians, inspire new ideas and innovations, and ultimately benefit patients and society. Readers can explore the diverse and exciting topics presented in this collection. We extend our gratitude to all authors and reviewers for their contributions to this Special Issue.

Format
  • Hardback
License
© 2024 by the authors; CC BY-NC-ND license
Keywords
epilepsy surgery; medically refractory focal epilepsy; presurgical evaluation; MRI-negative patients; discordant electroclinical and MRI data; metabolic PET; hybrid [18F]-FDG PET/MRI; preoperative workflow; concordance analysis; epilepsy team; aspirin resistance; genetic markers; genetics; machine learning; CatBoost; ischemic stroke; SNP; pharmacogenetics; platelet aggregation; biochip; primary headache; migraine; trigeminal system; CGRP; nNOS; neurogenic inflammation; animal model; inflammatory soup; dura mater; estrogen; behavior; respiratory sinus arrhythmia; directed information flow; neural pacemaker-like activity; fMRI-related anxiety; anxiety management; causal coupling; breathing rhythm; neural BOLD oscillations; cardio-respiratory coupling; breathing-entrained oscillations; transient receptor potential channels; antibody; reperfusion injury; middle cerebral artery occlusion; model; vascular; protection; hypoxia; stroke; therapy; age groups; attention; brain; cognition; default mode network; executive function; exercise; magnetic resonance imaging; memory; mental health; depression; cardiovascular disease; obesity; diabetes; civilization diseases; mental disorders; risk factors; inflammation; interleukins; comorbidity; cord blood stem cell transplantation; genetic vectors; vascular endothelial growth factor A; transcriptome; secretome; biosafety; genetic therapy; oxidative stresses; neuroinflammation; traumatic brain injuries; intensive care; sedatives; antioxidant effects; biologic monitoring; barbiturates; electron spin resonance; translational research; Parkinson’s disease; transcranial direct current stimulation; motor skill; cerebellum; cerebellar stimulation; motor learning; manual dexterity; dopamine; basal ganglia; transfer of motor learning; translational neuroscience; neuroplasticity; aphasia; rehabilitation; stroke; language impairment; cognitive recovery; brain; animals; language; physical health; psychosis; risk; CHR-P; n/a